$PSTV News

Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Plus Therapeutics’ CNSide Diagnostics Signs Regional Agreement With Medical Mutual Covering ~1.2M People Throughout Ohio And Kentucky, To Provide CNSide Cerebrospinal Fluid Tumor Cell Enumeration Assay

Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform

Plus Therapeutics Partners With Genomic Testing Cooperative To Integrate GTC's Next-Generation Sequencing Technology Into The CNSide Cerebrospinal Fluid Assay Platform

Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring

Plus Therapeutics Highlights Updated NCCN CNS Cancer Guidelines Reinforcing CSF Analysis In Leptomeningeal Metastases Care

Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding

Plus Therapeutics, Inc. (PSTV) Discusses Rebranding and Integrated CNS Oncology Platform Strategy Transcript

Plus Therapeutics Announces Name Change To Cerenome, With Nasdaq Trading Under Symbol 'CNSY,' Effective August 3; Reaffirms FY26 Milestone And Commercial Guidance

Plus Therapeutics to Provide Business Update Call on June 30, 2026

Ascendiant Capital Maintains Buy on Plus Therapeutics, Lowers Price Target to $57

Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform

Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory

Plus Therapeutics Subsidiary's Clinical Laboratory Gets Accreditation From College Of American Pathologists

Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases

Plus Therapeutics Presents New Data On Health Economics Trial Evaluating Economic Impact Of Earlier Detection And Therapeutic Management Of LM Through CNSide Cerebrospinal Fluid Assay

Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology

Plus Therapeutics Partners With Ephemeral Technologies To Deliver Unique AI Execution Platform For CNS Oncology

Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates

Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout